JAGX - ジャガ―・アニマル・ヘルス (Jaguar Health Inc.) ジャガ―・アニマル・ヘルス

 JAGXのチャート


 JAGXの企業情報

symbol JAGx
会社名 Jaguar Animal Health Inc (ジャガ―・アニマル・ヘルス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジャガー・ヘルス(Jaguar Health Inc.)(旧名:Jaguar Animal Health Inc.)は天然製品医薬品会社である。同社は人の処方箋使用及び動物のためのグローバルで、新規で持続可能な派生の消化器製品の開発及び製品化に従事する。Napo Pharmaceuticals Inc.を通じて、伝統的に熱帯雨林地域で使用される植物から、世界市場向けに独自のヒト胃腸薬を開発・商品化することを行う。Mytesiは、抗レトロウィルス療法に対するヒト免疫不全ウイルスHIV /後天性免疫不全症候群(AIDS)を有する成人患者における非感染性下痢の症候性軽減のために示される抗下痢剤である。他の製品はCanalevia、Equilevia、Neonorm Calf及びNeonorm Foalを含む。   ジャガ―・アニマル・ヘルスは米国の動物用医薬品メ―カ―。ペットや生産動物用の胃腸用治療薬の開発や商品化に焦点を当てる。主な薬品候補には、犬用の水溶性下痢治療処方薬「Canalevia」がある。また、非処方箋薬として、離乳前の酪農子牛用の水溶性下痢治療薬「Neonorm」を開発。本社はサンフランシスコ。   Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
本社所在地 201 Mission Street Suite 2375 San Francisco CA 94105 USA
代表者氏名 James J. Bochnowski ジェームズJ.ボノフノキ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 415-896-5081
設立年月日 41426
市場名 NASDAQ Small Cap
ipoyear 2015年
従業員数
url https://jaguar.health/
nasdaq_url https://www.nasdaq.com/symbol/jagx
adr_tso
EBITDA EBITDA(百万ドル) -19.94703
終値(lastsale) 0.5701
時価総額(marketcap) 28407706.734
時価総額 時価総額(百万ドル) 14.40071
売上高 売上高(百万ドル) 4.33046
企業価値(EV) 企業価値(EV)(百万ドル) 36.40752
当期純利益 当期純利益(百万ドル) -29.79644
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Jaguar Health Inc revenues decreased 2% to $1.7M. Net loss applicable to common stockholders increased from $6.5M to $14.3M. Revenues reflect Collaboration revenue decrease of 89% to $177K. Higher net loss reflects Sales and marketing expense increase from $280K to $4.4M (expense) Interest expense increase from $336K to $1.3M (expense) General and administrative expense increase of 11% to $6.1M (expense).

 JAGXのテクニカル分析


 JAGXのニュース

   The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration  2020/11/17 13:31:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16) Aligos Therapeutics Inc (NASDAQ: ALGS ) (announced multiple presentations at the Liver Meeting) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Champions Oncology Inc (NASDAQ: CSBR ) CureVac BV (NASDAQ: CVAC )(announced a vaccine supply deal with the European Commission) Eidos Therapeutics Inc (NASDAQ: EIDX ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kazia Therapeutics Ltd (NASDAQ: KZIA ) Keros Therapeutics Inc (NASDAQ: KROS ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim efficacy data for the Phase 3 study of its coronavirus vaccine candidate) Myokardia Inc (NASDAQ: MYOK ) Neuronetics Inc (NASDAQ: STIM ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacira Biosciences Inc (NASDAQ: PCRX ) Shockwave Medical Inc (NASDAQ: SWAV ) Spruce Biosciences Inc (NASDAQ: SPRB ) Summit Therapeutics Inc (NASDAQ: SMMT ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) (announced regulatory filing for envafolimab in the indication of MSI-H/dMMR cancer, in China) Trinity Biotech plc (NASDAQ: TRIB ) United Therapeutics Corporation (NASDAQ: UTHR ) Veracyte Inc (NASDAQ: VCYT ) Vericel Corp (NASDAQ: VCEL ) Zai Lab Ltd – ADR (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
   Jaguar Health EPS misses by $0.10, misses on revenue (NASDAQ:JAGX)  2020/11/16 13:10:05 Seeking Alpha
Jaguar Health (NASDAQ:JAGX): Q3 GAAP EPS of -$0.21 misses by $0.10. Revenue of $2.77M (+185.6% Y/Y) misses by $5.03M. Press Release
   The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings  2020/11/04 13:21:27 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 3) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) BioLineRx ADR Representing 15 Ord Shs (NASDAQ: BLRX )(reacted to positive readout for its stem cell therapy to treat cancer) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(reacted to its quarterly results) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) ( reported strong results for the third quarter) Immunovant Inc (NASDAQ: IMVT ) Scholar Rock Holding Corp (NASDAQ: SRRK ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 3) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aprea Therapeutics Inc (NASDAQ: APRE ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Benitec Biopharma Inc (NASDAQ: BNTC ) Esperion Therapeutics Inc (NASDAQ: ESPR ) (reacted to its quarterly results) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Jaguar Health Inc (NASDAQ: JAGX ) Liminal BioSciences Inc (NASDAQ: LMNL ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Opthea Spon (NASDAQ: OPT ) Silence Therapeutics ADR (NASDAQ: SLN ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Bristol-Myers Squibb Says Antitrust Waiting Period For Proposed Myokardia Acquisition Expires Bristol-Myers Squibb Co (NYSE: BMY ) said the waiting period under the HSR Act in connection with its previously announced tender offer to acquire …
   The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure  2020/11/03 12:38:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 2) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Immunovant Inc (NASDAQ: IMVT ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 2) AEterna Zentaris Inc. (NASDAQ: AEZS ) Aikido Pharma Inc (NASDAQ: AIKI ) Artelo Biosciences Inc (NASDAQ: ARTL ) Avita Therapeutics Inc (NASDAQ: RCEL ) Benitec Biopharma Inc (NASDAQ: BNTC ) BioCardia Inc (NASDAQ: BCDA ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Celsion Corporation (NASDAQ: CLSN ) Codiak BioSciences Inc (NASDAQ: CDAK ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) FSD Pharma Inc (NASDAQ: HUGE ) Galecto Inc (NASDAQ: GLTO ) (went public Thursday) Hoth Therapeutics Inc (NASDAQ: HOTH ) Inhibrx Inc (NASDAQ: INBX ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Monopar Therapeutics Inc (NASDAQ: MNPR ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) (halted dosing in Strimvelis study after it was linked to the development of leukemia in a patient) Orphazyme A S ADR (NASDAQ: ORPH ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) Stocks In Focus Aurinia Ends Dry Eye Disease Study Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) said topline results from its Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution for the potential treatment of …
   The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO  2020/10/23 11:26:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Kodiak Sciences Inc (NASDAQ: KOD ) Nevro Corp (NYSE: NVRO ) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) (priced its common stock offering of 4.69 million shares at $40 apiece. Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 22) Artelo Biosciences Inc (NASDAQ: ARTL ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Aziyo Biologics Inc (NASDAQ: AZYO ) DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its $15 million worth of common stock offering) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Metacrine Inc (NASDAQ: MTCR ) Rockwell Medical Inc (NASDAQ: RMTI ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Stocks In Focus Akebia Presents Positive Phase 3 Data For Anemia Drug In Chronic Kidney Disease Patients Akebia Therapeutics Inc (NASDAQ: AKBA ) presented at the American Society of Nephrology Kidney Week 2020 Reimagined, …
   The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO  2020/10/23 11:26:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Kodiak Sciences Inc (NASDAQ: KOD ) Nevro Corp (NYSE: NVRO ) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) (priced its common stock offering of 4.69 million shares at $40 apiece. Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 22) Artelo Biosciences Inc (NASDAQ: ARTL ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Aziyo Biologics Inc (NASDAQ: AZYO ) DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its $15 million worth of common stock offering) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Metacrine Inc (NASDAQ: MTCR ) Rockwell Medical Inc (NASDAQ: RMTI ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Stocks In Focus Akebia Presents Positive Phase 3 Data For Anemia Drug In Chronic Kidney Disease Patients Akebia Therapeutics Inc (NASDAQ: AKBA ) presented at the American Society of Nephrology Kidney Week 2020 Reimagined, …
   Jaguar Health (NASDAQ:JAGX) Shares Down 7.6%  2020/10/22 20:18:45 US Banking News
Jaguar Health, Inc. (NASDAQ:JAGX) shares fell 7.6% on Thursday . The company traded as low as $0.25 and last traded at $0.27. 7,792,117 shares traded hands during mid-day trading, an increase of 126% from the average session volume of 3,440,393 shares. The stock had previously closed at $0.29. Separately, Zacks Investment Research cut shares of […]
   Jaguar Health CEO And Lead Ethnobotanical Researcher Explain The Decades Of Research That Made It A Leader In Plant-Based Drug Treatment  2020/10/21 11:45:52 Benzinga
The following post is sponsored by Jaguar Health, Inc. It is for informational purposes only and not intended to be investing advice. With more than 30 years of ethnobotanical field research and ethnopharmacological compound analysis encompassing plant species and medical traditions from indigenous communities throughout the world’s rainforest and tropical biomes, the management team at Jaguar Health (NASDAQ: JAGX ) has garnered a unique reservoir of knowledge and expertise within the biotech industry. The first fruits of this knowledge catalog yielded the company’s lead drug compound, crofelemer, which is marketed under the trade name Mytesi as a first-in-class, botanically-derived, antisecretory agent indicated for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. As the only oral plant-based prescription medicine approved under FDA botanical guidance, crofelemer represents a new paradigm in refining and applying traditional medical practices into contemporary Western healthcare.
   Jaguar Health CEO Discusses Upcoming Virtual Event Highlighting Long-Term Treatment Needs Of Cancer Patients  2020/10/15 11:29:38 Benzinga
The following post is sponsored by Jaguar Health, Inc. It is for informational purposes only and not intended to be investing advice. Next Tuesday, October 20th, Jaguar Health, Inc. (NASDAQ: JAGX ) will hold a live virtual webinar intended for investors that will bring together experts in patient support, medical oncology and pharmaceutical research to discuss the current landscape of supportive care for cancer patients. The first-in-kind event, Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer , aims to raise awareness in the investor community about the need for supportive care for people experiencing conditions related to chronic lower gastrointestinal tract distress — specifically, the debilitating diarrhea that often results from cancer and cancer therapy, also known as cancer therapy-related diarrhea. The event will shed light on existing diarrhea management regimens, their associated limitations and impact on patient comfort and quality-of-life and Jaguar’s related ongoing drug development program of interest to investors and the business community.
   Thinking about buying stock in Jaguar Health, Oragenics, Plug Power, FuelCell Energy, or Norwegian Cruise Line?  2020/10/06 14:45:00 PR Newswire
NEW YORK, Oct. 6, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, OGEN, PLUG, FCEL, and NCLH. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Jaguar Health CEO And Lead Ethnobotanical Researcher Explain The Decades Of Research That Made It A Leader In Plant-Based Drug Treatment  2020/10/21 11:45:52 Benzinga
The following post is sponsored by Jaguar Health, Inc. It is for informational purposes only and not intended to be investing advice. With more than 30 years of ethnobotanical field research and ethnopharmacological compound analysis encompassing plant species and medical traditions from indigenous communities throughout the world’s rainforest and tropical biomes, the management team at Jaguar Health (NASDAQ: JAGX ) has garnered a unique reservoir of knowledge and expertise within the biotech industry. The first fruits of this knowledge catalog yielded the company’s lead drug compound, crofelemer, which is marketed under the trade name Mytesi as a first-in-class, botanically-derived, antisecretory agent indicated for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. As the only oral plant-based prescription medicine approved under FDA botanical guidance, crofelemer represents a new paradigm in refining and applying traditional medical practices into contemporary Western healthcare.
   Jaguar Health CEO Discusses Upcoming Virtual Event Highlighting Long-Term Treatment Needs Of Cancer Patients  2020/10/15 11:29:38 Benzinga
The following post is sponsored by Jaguar Health, Inc. It is for informational purposes only and not intended to be investing advice. Next Tuesday, October 20th, Jaguar Health, Inc. (NASDAQ: JAGX ) will hold a live virtual webinar intended for investors that will bring together experts in patient support, medical oncology and pharmaceutical research to discuss the current landscape of supportive care for cancer patients. The first-in-kind event, Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer , aims to raise awareness in the investor community about the need for supportive care for people experiencing conditions related to chronic lower gastrointestinal tract distress — specifically, the debilitating diarrhea that often results from cancer and cancer therapy, also known as cancer therapy-related diarrhea. The event will shed light on existing diarrhea management regimens, their associated limitations and impact on patient comfort and quality-of-life and Jaguar’s related ongoing drug development program of interest to investors and the business community.
   Thinking about buying stock in Jaguar Health, Oragenics, Plug Power, FuelCell Energy, or Norwegian Cruise Line?  2020/10/06 14:45:00 PR Newswire
NEW YORK, Oct. 6, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, OGEN, PLUG, FCEL, and NCLH. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Jaguar Health secures first tranche related to sale of Mytesi royalties (NASDAQ:JAGX)  2020/10/06 13:18:53 Seeking Alpha
Jaguar Health (NASDAQ:JAGX) jumps 16% premarket after it met the financial condition for the initial $5M tranche of the previously announced non-dilutive r
   Jaguar Health Meets Financial Condition for Sale of Royalty Rights for Mytesi (Crofelemer) Indications  2020/10/06 12:30:00 Yahoo Finance
(NASDAQ:JAGX) today announced that the company has met the financial condition for the initial $5 million tranche of the previously announced non-dilutive royalty financing transaction - which has the potential to total $16 million - involving the sale of royalty rights related to the future revenue

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジャガ―・アニマル・ヘルス JAGX Jaguar Health Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)